← All trials
NCT07179081
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2020
- Primary completion
- Jan 26, 2026
- Completion date
- Jan 26, 2026
- First posted
- Sep 17, 2025
- Last posted
- Sep 17, 2025
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Advenchen Laboratories, LLCLead sponsor
- Central South UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.